Drug Trial Radar · NCT07790575
Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jul 2041
Study completion Jul 2041
Sponsor
- Lead sponsor
- Saurabh DahiyaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).
Conditions
- Cytopenia
Interventions
AZD0120Drug
One time administration on Day 0.
BendamustinDrug
Participants will be given bendamustin for 2 days (study Day -5 and Day -4) followed by 3 days of rest.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: within 28 days after the CAR-T administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.